The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is modified

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 3, 2014, Pages 1180-1185

  Movérare Skrtic, Sofia ^a   Börjesson, Anna E ^a   Farman, Helen H ^a   Sjögren, Klara ^a   Windahl, Sara H ^a   Lagerquist, Marie K ^a   Andersson, Annica ^a   Stubelius, Alexandra ^a   Carlsten, Hans ^a   Gustafsson, Jan Åke ^b   Ohlsson, Claes ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA AF 2; FULVESTRANT; LASOFOXIFENE; RALOXIFENE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

AGONIST; ANIMAL EXPERIMENT; ARTICLE; BODY FAT; BODY HEIGHT; BODY WEIGHT; BONE GROWTH; BONE MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); CROWN RUMP LENGTH; FAT MASS; FEMALE; FEMUR; GENE MUTATION; GROWTH PLATE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; THYMUS; TRABECULAR BONE; UTERUS WEIGHT; WILD TYPE;

ADIPOSE TISSUE; ANIMALS; BONE AND BONES; BONE MARROW CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; INSULIN-LIKE GROWTH FACTOR I; LIGANDS; MICE; MUTATION; ORGAN SIZE; PROTEIN STRUCTURE, TERTIARY; PYRROLIDINES; RALOXIFENE; RECEPTORS, ESTROGEN; TETRAHYDRONAPHTHALENES; THYMUS GLAND; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; UTERUS; X-RAY MICROTOMOGRAPHY;

EID: 84892915929     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1322910111     Document Type: Article

References (43)

1. Khosla S, Melton LJ 3rd, Riggs BL (2011) The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: Is a revision needed? J Bone Miner Res 26(3):441-451.
2. Mellström D, et al. (2008) Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23(10):1552-1560.
3. Smith EP, et al. (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331(16):1056-1061.
4. Vandenput L, Ohlsson C (2009) Estrogens as regulators of bone health in men. Nat Rev Endocrinol 5(8):437-443.
5. Daly E, et al. (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348(9033):977-980.
6. Anonymous Collaborative Group on Hormonal Factors in Breast Cancer; Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350(9084):1047-1059.
7. Mödder UI, et al. (2008) The skeletal response to estrogen is impaired in female but not in male steroid receptor coactivator (SRC)-1 knock out mice. Bone 42(2):414-421.
8. Movérare S, et al. (2003) Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci USA 100(23):13573-13578.
9. Sims NA, et al. (2003) A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J Clin Invest 111(9):1319-1327.
10. Tora L, et al. (1989) The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59(3):477-487.
11. McKenna NJ, Lanz RB, O'Malley BW (1999) Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 20(3):321-344.
12. Börjesson AE, et al. (2011) Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. Proc Natl Acad Sci USA 108(15):6288-6293.
13. Borjesson AE, et al. (2012) The role of activation functions 1 and 2 of estrogen receptor-a for the effects of estradiol and Selective Estrogen Receptor Modulators (SERMs) in male mice. J Bone Miner Res 28(5):1117-1126.
14. Brzozowski AM, et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389(6652):753-758.
15. Wu YL, et al. (2005) Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18(4):413-424.
16. Valentine JE, Kalkhoven E, White R, Hoare S, Parker MG (2000) Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J Biol Chem 275(33):25322-25329.
17. Ince BA, Zhuang Y, Wrenn CK, Shapiro DJ, Katzenellenbogen BS (1993) Powerful dominant negative mutants of the human estrogen receptor. J Biol Chem 268(19):14026-14032.
18. Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS (1996) Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10(3):230-242.
19. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W (1995) Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92(10):4206-4210.
20. Nicholson RI, et al. (1995) Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci 761:148-163.
21. Bross PF, Cohen MH, Williams GA, Pazdur R (2002) FDA drug approval summaries: Fulvestrant. Oncologist 7(6):477-480.
22. Arao Y, et al. (2011) Estrogen receptor α AF-2 mutation results in antagonist reversal and reveals tissue selective function of estrogen receptor modulators. Proc Natl Acad Sci USA 108(36):14986-14991.
23. Vanderschueren D, et al. (2000) Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model. Bone 27(5):611-617.
24. Juul A (2001) The effects of oestrogens on linear bone growth. Hum Reprod Update 7(3):303-313.
25. Jansson JO, Edén S, Isaksson O (1985) Sexual dimorphism in the control of growth hormone secretion. Endocr Rev 6(2):128-150.
26. Ohlsson C, et al. (2009) The role of liver-derived insulin-like growth factor-I. Endocr Rev 30(5):494-535.
27. Veldhuis JD, et al. (1997) Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo- somatotrope (growth hormone)-insulin-like growth factor I axis in the human: Evidence from pubertal pathophysiology and sex-steroid hormone replacement. J Clin Endocrinol Metab 82(10):3414-3420.
28. Arao Y, Hamilton KJ, Coons LA, Korach KS (2013) Estrogen receptor α L543A, L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity. J Biol Chem 288(29):21105-21116.
29. Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89(9):4037-4041.
30. Gibson MK, et al. (1991) The mechanism of ICI 164, 384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129(4):2000-2010.
31. Hilmi K, et al. (2012) Role of SUMOylation in full antiestrogenicity. Mol Cell Biol 32(19):3823-3837.
32. Lupien M, et al. (2007) Raloxifene and ICI182, 780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12. Mol Endocrinol 21(4):797-816.
33. Ohlsson C, et al. (2000) Obesity and disturbed lipoprotein profile in estrogen receptoralpha-deficient male mice. Biochem Biophys Res Commun 278(3):640-645.
34. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS (2000) Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 97(23):12729-12734.
35. Métivier R, Penot G, Flouriot G, Pakdel F (2001) Synergism between ERalpha transactivation function 1(AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: Requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains. Mol Endocrinol 15 (11):1953-1970.
36. Mödder UI, et al. (2004) Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology 145(2):913-921.
37. Rochira V, Carani C (2009) Aromatase deficiency in men: A clinical perspective. Nat Rev Endocrinol 5(10):559-568.
38. Börjesson AE, et al. (2010) The role of estrogen receptor α in growth plate cartilage for longitudinal bone growth. J Bone Miner Res 25(12):2690-2700.
39. Börjesson AE, et al. (2012) The role of estrogen receptor-α and its activation function-1 for growth plate closure in female mice. Am J Physiol Endocrinol Metab 302(11):E1381-E1389.
40. Milligan G, Bond RA, Lee M (1995) Inverse agonism: Pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16(1):10-13.
41. Morisset S, et al. (2000) High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408(6814):860-864.
42. Nijenhuis WA, Garner KM, van Rozen RJ, Adan RA (2003) Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J Biol Chem 278(25):22939-22945.
43. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C (1999) Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta (-/-) mice. J Clin Invest 104(7):895-901.